secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axcella Health Inc. (—)
CIK:        0001633070
Form:       8-K
Filed at:   2022-12-15T23:59:59+00:00
Accession:  0001104659-22-127154
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axcella cuts 85% workforce, suspends NASH trial, focuses on Long COVID
----------------------------------------------------------------------

- Board approves reduction in force of ~85%, affecting CFO Robert Crane and Chief People Officer Virginia Dean, effective Dec 14.
- Records Q4 2022 restructuring charge of up to $2.1M for severance and related costs.
- Immediately suspends EMMPACT Phase 2b trial of AXA1125 for NASH to focus on Long COVID Fatigue.
- Reaches agreement with SLR Investment Corp. to pay down remaining debt under Loan and Security Agreement.
- Initiates strategic alternatives review with investment bank to maximize shareholder value; no assurances of transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1633070/000110465922127154/0001104659-22-127154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1633070/000110465922127154/tm2232767d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-127154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer